Bengaluru-based longevity science startup Decode Age has raised Rs 14.48 crore (around $1.7 million) in a Pre-Series A funding round, according to people familiar with the development. The round was led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India. The fresh capital marks a key milestone for the company as it deepens its focus on ageing biology, gut microbiome research, and biomarker discovery.
Founded in 2021, Decode Age operates at the intersection of biotechnology, data science, and preventive healthcare. The startup is working to decode the biological processes of ageing and translate complex scientific data into actionable health insights. With this funding, the company aims to strengthen its research backbone and scale its scientific ambitions from India to a global stage.
Decode AgeExpanding Research Capabilities and Infrastructure
A large portion of the newly raised capital will be used to expand Decode Age’s research and development capabilities. The company plans to invest in advanced laboratory infrastructure, improve its analytical platforms, and accelerate biomarker discovery programmes. These efforts are expected to enhance the accuracy and depth of its ageing-related research.
Decode Age is also looking to scale its multi-omics and microbiome research, which involves studying genes, proteins, metabolites, and gut bacteria together to gain a holistic understanding of human health and ageing. This integrated approach allows the startup to identify biological patterns linked to longevity, chronic inflammation, metabolism, and cognitive health.
Focus on Ageing Biology and Gut Microbiome
At the core of Decode Age’s work is a strong emphasis on ageing biology and gut microbiome science. The company has built an integrated research platform that combines genome-scale microbiome analysis, metagenomics, and biological marker studies. These tools help decode how internal biological systems change over time and how lifestyle, nutrition, and environment influence ageing.
The gut microbiome, in particular, has emerged as a critical area of focus. Scientific research increasingly shows that gut health plays a major role in immunity, metabolic balance, brain health, and overall longevity. Decode Age aims to generate India-specific data in this space, an area that has traditionally been under-researched in global studies.
Developing Science-Backed Longevity Solutions
Beyond research, Decode Age is also developing evidence-based longevity and wellness solutions. These include research-driven supplements and interventions designed to support cellular health, energy metabolism, and inflammation control. The company’s product development strategy is rooted in scientific validation rather than trends, with a strong emphasis on data-led outcomes.
The funding will also support the expansion of the company’s scientific and product teams. By bringing in more researchers and specialists, Decode Age aims to speed up innovation cycles and strengthen the link between laboratory findings and real-world health applications.
Long-Term Vision and India’s Growing Biotech Role
The participation of Dr Krishna Prasad Chigurupati in the round reflects growing investor confidence in longevity science as a long-term healthcare opportunity. Industry experts believe Decode Age’s work has the potential to reshape how ageing and preventive health are approached in India.
Looking ahead, Decode Age plans to deepen collaborations with academic institutions and global research initiatives. The startup wants to position India as an important contributor to global longevity research while making advanced biological insights accessible to clinicians, researchers, and individuals alike.
With this Pre-Series A funding, Decode Age joins a growing list of Indian biotech startups pushing the boundaries of science-led healthcare. As awareness around healthy ageing and preventive medicine continues to rise, the company is betting on rigorous research and data-driven innovation to define the future of longevity science in India.